Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 117

Similar articles for PubMed (Select 23263823)

1.

Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.

Tang PA, Heng DY.

Curr Oncol Rep. 2013 Apr;15(2):98-104. doi: 10.1007/s11912-012-0284-2. Review.

PMID:
23263823
2.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M.

N Engl J Med. 2012 Jun 28;366(26):2443-54. doi: 10.1056/NEJMoa1200690. Epub 2012 Jun 2.

3.

PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.

Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G.

Cancer Treat Rev. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6. Review.

PMID:
25586601
4.

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL.

J Clin Oncol. 2010 Jul 1;28(19):3167-75. doi: 10.1200/JCO.2009.26.7609. Epub 2010 Jun 1.

5.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, Salay TM, Alaparthy S, Grosso JF, Korman AJ, Parker SM, Agrawal S, Goldberg SM, Pardoll DM, Gupta A, Wigginton JM.

N Engl J Med. 2012 Jun 28;366(26):2455-65. doi: 10.1056/NEJMoa1200694. Epub 2012 Jun 2.

6.

Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.

Tripathi A, Drake CG, Harshman LC.

BioDrugs. 2014 Dec;28(6):513-26. doi: 10.1007/s40259-014-0111-4. Review.

PMID:
25445176
7.

Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions.

Pal SK, Hu A, Chang M, Figlin RA.

Clin Adv Hematol Oncol. 2014 Feb;12(2):90-9. Review.

PMID:
24892254
8.

PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.

Harshman LC, Drake CG, Choueiri TK.

Cancer Immunol Res. 2014 Dec;2(12):1132-41. doi: 10.1158/2326-6066.CIR-14-0193. Review.

PMID:
25480555
9.

PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer.

Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM.

J Immunother. 2012 Feb-Mar;35(2):169-78. doi: 10.1097/CJI.0b013e318247a4e7.

PMID:
22306905
10.

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Hamid O, Carvajal RD.

Expert Opin Biol Ther. 2013 Jun;13(6):847-61. doi: 10.1517/14712598.2013.770836. Epub 2013 Feb 19. Review.

PMID:
23421934
11.

[Anti-PD-1 antibody: basics and clinical application].

Tanaka Y, Okamura H.

Gan To Kagaku Ryoho. 2013 Sep;40(9):1145-9. Japanese.

PMID:
24047772
12.

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.

Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A.

Int J Cancer. 2006 Jul 15;119(2):317-27.

PMID:
16482562
13.

Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy.

Sznol M.

Cancer J. 2014 Jul-Aug;20(4):290-5. doi: 10.1097/PPO.0000000000000056. Review.

PMID:
25098290
14.

Programmed death-1 pathway in cancer and autoimmunity.

Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A.

Clin Immunol. 2014 Jul;153(1):145-52. doi: 10.1016/j.clim.2014.04.010. Epub 2014 Apr 26. Review.

PMID:
24780173
15.

Prospects for targeting PD-1 and PD-L1 in various tumor types.

Kim JW, Eder JP.

Oncology (Williston Park). 2014 Nov;28 Suppl 3:15-28. Review.

16.

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y.

Clin Cancer Res. 2007 Apr 1;13(7):2151-7.

17.

[Targeting the PD-1/PD-L1 immune checkpoint signal - a new treatment strategy for cancer].

Hamanishi J, Konishi I.

Gan To Kagaku Ryoho. 2014 Sep;41(9):1071-6. Japanese.

PMID:
25248890
18.

Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies.

Bracarda S, Altavilla A, Hamzaj A, Sisani M, Marrocolo F, Del Buono S, Danielli R.

Semin Oncol. 2015 Jun;42(3):495-505. doi: 10.1053/j.seminoncol.2015.02.004. Epub 2015 Feb 12. Review.

PMID:
25965369
19.

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Topalian SL, Drake CG, Pardoll DM.

Curr Opin Immunol. 2012 Apr;24(2):207-12. doi: 10.1016/j.coi.2011.12.009. Epub 2012 Jan 9. Review.

20.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk